4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0000950170-25-023385
Chief Executive Officer sold 18,568 shares at an average $54.21 ($1,006,580)
- Chief Executive Officer acquired 13,250 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2025-02-18 | Option exercise 10b5-1 | +13,250 | 208,541 | D | ||
| Kulkarni Samarth Chief Executive Officer | 2025-02-18 | Sale 10b5-1 | −11,640 | $55.05 | $640,782 | 196,901 | D |
| Kulkarni Samarth Chief Executive Officer | 2025-02-19 | Sale 10b5-1 | −6,928 | $52.80 | $365,798 | 189,973 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2025-02-18 | Option exercise · Restricted Stock Units 10b5-1 | −13,250 | 13,250 | D | ||
| Open-market sales · 18,568 sh · avg $54.21 · $1,006,580 | |||||||
Loading xslF345X05/ownership.xml…